<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348683</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1441</org_study_id>
    <nct_id>NCT03348683</nct_id>
  </id_info>
  <brief_title>Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients</brief_title>
  <official_title>Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective trial will be offered to women admitted to the labor floors at
      Mount Sinai Medical Center for labor induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of labor is a common obstetric procedure, which is performed to provoke the onset
      of labor and lead to delivery of the fetus. While some early studies suggested a possible
      increased rate of cesarean with induction of labor, more recent meta-analyses have shown that
      induction does not influence this rate. There is data from small randomized studies that
      demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for induction of
      labor. This literature suggests a decrease in the amount of time to delivery and a possible
      reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for
      induction of labor compared to oxytocin alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study drug and placebo will be randomized and mixed to appear identical by the Mount Sinai Investigational Drug Service (IDS). The randomization code will be kept by the lead pharmacist of the IDS until completion of the trial, at which point data will be unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time from beginning of induction to delivery</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mode of Delivery</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of latent versus active labor</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>Time of latent labor defined as &lt;6cm of cervical dilation. Time of active labor will be defined as &gt;6cm of cervical dilation until full dilation, at which point the second stage of labor will commence (pushing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite score of maternal side effects</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Composite maternal side effects score will consist of count of hypotension &lt;80/40 within 30 minutes of study drug administration, bradycardia &lt;50 bpm within 30 minutes of study drug administration, bronchospasm, allergic reaction (rash, urticaria, angioedema or anaphylaxis). Each component will be given a weighted score to come up with a total composite score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fetus with heart rate decelerations</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fetus with fetal bradycardia</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Count of fetus with fetal bradycardia (&lt;110bpm for &gt;10 minutes within 30 minutes of study drug administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite score neonatal outcome</measure>
    <time_frame>Day 1</time_frame>
    <description>Composite neonatal outcome score will consist of birth weight, APGAR score - (baby's color, heart rate, reflexes, muscle tone and respiratory effort. APGAR scores range from zero to two for each condition with a maximum final total score of ten.), NICU admission. Each component will be given a weighted score to come up with a total composite score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>Day 1</time_frame>
    <description>Neonatal outcome - Number of neonates with hypoglycemia (blood glucose &lt;50)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg of IV push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an equivalent quantity in milliliters of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous women undergoing induction of labor

          -  &gt;37 weeks' gestational age

          -  Non-anomalous, singleton cephalic presenting fetus.

        Exclusion Criteria:

          -  Multiple gestations, known fetal anomalies

          -  Maternal cardiac or hypertensive disease

          -  Chronic beta blocker use

          -  Bronchial asthma

          -  Maternal or fetal indication for immediate delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant patients are the only subjects eligible for study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Stone, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Stone, MD, MS</last_name>
    <phone>212-241-568</phone>
    <email>joanne.stone@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Bigelow, MD</last_name>
    <phone>212-241-2974</phone>
    <email>catherine.bigelow1@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bigelow, MD</last_name>
      <phone>212-241-2974</phone>
      <email>catherine.bigelow1@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Stone, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>BLACK JW, CROWTHER AF, SHANKS RG, SMITH LH, DORNHORST AC. A NEW ADRENERGIC BETARECEPTOR ANTAGONIST. Lancet. 1964 May 16;1(7342):1080-1.</citation>
    <PMID>14132613</PMID>
  </reference>
  <reference>
    <citation>Moghadam AD, Jaafarpour M, Khani A. Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial). J Clin Diagn Res. 2013 Nov;7(11):2567-9. doi: 10.7860/JCDR/2013/5704.3613. Epub 2013 Nov 10. Erratum in: J Clin Diagn Res. 2015 Aug;9(8):ZZ01.</citation>
    <PMID>24392402</PMID>
  </reference>
  <reference>
    <citation>Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol Res. 2008 Jun;34(3):354-8. doi: 10.1111/j.1447-0756.2008.00790.x.</citation>
    <PMID>18588611</PMID>
  </reference>
  <reference>
    <citation>Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD. Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2016 Apr;293(4):721-9. doi: 10.1007/s00404-015-3991-8. Epub 2015 Dec 22. Review.</citation>
    <PMID>26695642</PMID>
  </reference>
  <reference>
    <citation>Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485-9.</citation>
    <PMID>573555</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996 Oct;88(4 Pt 1):517-20.</citation>
    <PMID>8841209</PMID>
  </reference>
  <reference>
    <citation>Ikeda S, Tamaoki H, Akahane M, Nebashi Y. Effects of ritodrine hydrochloride, a beta 2-adrenoceptor stimulant, on uterine motilities in late pregnancy. Jpn J Pharmacol. 1984 Jul;35(3):319-26.</citation>
    <PMID>6482092</PMID>
  </reference>
  <reference>
    <citation>Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185. Print 2012.</citation>
    <PMID>22815467</PMID>
  </reference>
  <reference>
    <citation>Omar HA, Rhodes LA, Ramirez R, Arsich J, Einzig S. Alteration of human placental vascular tone by antiarrhythmic medications in vitro. J Cardiovasc Electrophysiol. 1996 Dec;7(12):1197-203.</citation>
    <PMID>8985808</PMID>
  </reference>
  <reference>
    <citation>Palomäki O, Uotila J, Tammela O, Kaila T, Lavapuro M, Huhtala H, Tuimala R. A double blind, randomized trial on augmentation of labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):44-9. Epub 2005 Jul 26.</citation>
    <PMID>16051416</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Joanne Stone</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Induction</keyword>
  <keyword>Labor</keyword>
  <keyword>Propranolol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

